Table 4. Individual immunohistochemical values.
| Animal No. | HE | CD31 | Ki-67 | TUNEL | VEGFR2 |
|---|---|---|---|---|---|
| THERAPY GROUP | |||||
| 1 | 66.9 | 7.7 | 286.6 | 345.9 | 6.3 |
| 2 | 61.9 | 10.2 | 232.3 | 858.3 | 9.5 |
| 3 | 62.7 | 10.2 | 349.7 | 613.5 | 8.2 |
| 4 | 33.7 | 10.1 | 412.1 | 436.4 | 8.2 |
| 5 | 70.7 | 4.0 | 265.3 | 739.5 | 5.9 |
| 6 | 55.0 | 9.7 | 233.8 | 781.4 | 7.5 |
| 7 | 57.7 | 9.8 | 330.8 | 936.4 | 5.8 |
| 8 | 35.2 | 3.7 | 216.8 | 582.1 | 3.3 |
| 9 | 50.8 | 3.0 | 289.2 | 574.8 | 7.7 |
| 10 | 73.1 | 10.4 | 537.3 | n/a | 9.1 |
| 11 | 76.4 | 9.8 | 352.2 | 858.2 | 7.0 |
| Mean | 58.6* | 8.1* | 318.7* | 672.7* | 7.2* |
| SD | 14.2 | 3.0 | 94.0 | 194.0 | 1.8 |
| CONTROL GROUP | |||||
| 12 | 21.9 | 30.2 | 338.7 | 597.2 | 16.9 |
| 13 | 16.8 | 23.5 | 449.6 | 464.6 | 24.6 |
| 14 | 18.3 | 19.5 | 300.8 | 390.5 | 16.8 |
| 15 | 14.3 | 18.8 | 597.9 | 152.8 | 16.0 |
| 16 | 22.5 | 27.4 | 370.9 | 480.4 | 20.1 |
| 17 | 11.8 | 10.5 | 583.5 | 326.8 | 18.8 |
| 18 | 8.3 | 22.5 | 414.0 | 34.6 | 22.3 |
| 19 | 31.6 | 14.3 | 592.5 | 423.6 | 15.3 |
| 20 | 18.3 | 21.0 | 352.6 | 570.8 | 7.6 |
| 21 | 19.0 | 20.3 | 679.5 | 134.9 | 19.4 |
| Mean | 18.3* | 20.8* | 468.0* | 357.6* | 17.8* |
| SD | 6.4 | 5.7 | 133.8 | 192.0 | 4.6 |
Individual values for the investigated histological and immunohistochemical parameters of tumor necrosis (HE), tumor microvascular density (CD31), tumor cell proliferation (Ki-67), tumor cell apoptosis (TUNEL) and VEGFR2 expression in the therapy and in the control group. Note the significantly higher necrosis rate (%) and higher number of apoptotic cells as well as the significantly lower tumor vascularity, tumor cell proliferation and VEGFR2 expression in the regorafenib-treated therapy group.
* significant difference (p < 0.01) between therapy and control group
n/a = not available due to technical issues